(Q46319345)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

David L Veenstra

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

937-949

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200826110-00006

15 January 2020

exact match

0 references

cites work

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200826110-00006

Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200826110-00006

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200826110-00006

Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection?

1 reference

12 December 2020

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

12 December 2020

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

12 December 2020

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

1 reference

12 December 2020

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

1 reference

12 December 2020

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.

1 reference

12 December 2020

Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden

1 reference

12 December 2020

Hepatitis B virus infection--natural history and clinical consequences

1 reference

12 December 2020

Representing uncertainty: the role of cost-effectiveness acceptability curves

1 reference

12 December 2020

Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis

1 reference

12 December 2020

Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation

1 reference

12 December 2020

1 reference

12 December 2020

The search for cost-effective treatment of chronic hepatitis B.

1 reference

12 December 2020

Cost of chronic hepatitis B infection in the United States.

1 reference

12 December 2020

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

12 December 2020

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

12 December 2020

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis

1 reference

12 December 2020

The maze of treatments for hepatitis B

1 reference

12 December 2020

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

1 reference

12 December 2020

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

12 December 2020

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

12 December 2020

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

12 December 2020

Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom

1 reference

12 December 2020

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Global epidemiology of hepatitis B virus

1 reference

12 December 2020

Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B

1 reference

12 December 2020

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

12 December 2020

Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients

1 reference

12 December 2020

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty

1 reference

12 December 2020

Potency of tenofovir in chronic hepatitis B: mono or combination therapy?

1 reference

12 December 2020

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

1 reference

12 December 2020

Chronic hepatitis B: current epidemiology in the Americas and implications for management.

1 reference

12 December 2020

10.2165/00019053-200826110-00006

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18850763%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

15 January 2020

1040419180

0 references

1 reference